EFTR News and Press, eFFECTOR Therapeutics Inc. From 01/25/24

2024-01-25 08:25:44 ET More on Pre-market losers & stocks. LG Display Co Ltd (LPL) Q4 2023 Earnings Call Transcript LG Display: It Is The Long-Term Picture That Is Giving People Pause Silo Pharma stock rises after inking exclusive license deal with Medspray Pharm...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced...

2024-01-11 08:02:08 ET Effector Therapeutics Inc (EFTR) announced stock split at a ratio of 1-for-25 on 2024-01-12 ... Full story available on KlickAnalytics.com

2024-01-09 08:22:33 ET More on eFFECTOR Therapeutics eFFECTOR updates Phase 1/2 data for breast cancer therapy eFFECTOR stock rises after FDA fast track status for breast cancer therapy Seeking Alpha’s Quant Rating on eFFECTOR Therapeutics Historical e...

-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients- -  ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that its Board of Directors (...

2023-12-08 09:04:17 ET More on eFFECTOR Therapeutics eFFECTOR stock rises after FDA fast track status for breast cancer therapy Seeking Alpha’s Quant Rating on eFFECTOR Therapeutics Historical earnings data for eFFECTOR Therapeutics Financial informati...

Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Zotatifin generally well tolerated as dose escalation continues; Currently enrolling at 0.28 mg/kg in...

2023-11-30 13:03:20 ET More on eFFECTOR Therapeutics eFFECTOR stock rises after FDA fast track status for breast cancer therapy Seeking Alpha’s Quant Rating on eFFECTOR Therapeutics Historical earnings data for eFFECTOR Therapeutics Financial informati...

Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be presented at 2023 San Antonio Breast Cancer Symposium (SABCS) ...